Cabaletta Bio (CABA) Projected to Post Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Cabaletta Bio to post earnings of ($0.66) per share for the quarter.

Cabaletta Bio Stock Down 1.4 %

Shares of Cabaletta Bio stock traded down $0.03 on Friday, hitting $1.73. 656,931 shares of the company's stock traded hands, compared to its average volume of 1,481,795. Cabaletta Bio has a 52-week low of $1.59 and a 52-week high of $19.04. The stock has a market cap of $84.31 million, a P/E ratio of -0.79 and a beta of 2.58. The firm's 50-day moving average is $2.19 and its 200 day moving average is $3.12.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CABA. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of Cabaletta Bio in a research note on Tuesday, February 18th. Wells Fargo & Company cut shares of Cabaletta Bio from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. Evercore ISI cut Cabaletta Bio from an "outperform" rating to an "inline" rating and cut their price target for the company from $15.00 to $6.00 in a report on Friday, December 20th. Finally, TD Cowen upgraded Cabaletta Bio to a "strong-buy" rating in a research report on Friday, November 29th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $22.71.

Remove Ads

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.